Developments: Biogen (Archives 2011 -2015)

Parents

2011: Biogen Idec Buys Drug Rights from Neurimmune for $32.5M (2010)
2011: Biogen Idec, Inc. (Massachusetts) (BIIB), Portola Pharmaceuticals, Inc. Strike $553 Million Deal for Oral Syk Inhibitor (2011)
2011: Samsung, Biogen Idec form $300M biosimilars joint venture (2011)
2013: Biogen Idec Strikes $100M Upfront Deal With Isis for Neurology (2013)
2013: Proteostasis, Biogen Team up on Protein Homeostasis Drugs
2014: 2014: Biogen Idec forges a $320M gene editing deal aimed at curing inherited blood disorders (2014)
2014: Biogen Stock, Punished in Selloff, Can Rise 20%
2014: Biogen to take part in $230M NIH partnership on drugs for Alzheimerâ™s
2014: Biogen, Eisai Join Up in Alzheimer’s Drug Pact
2014: Biogenâ™s Tecfidera on track to hit blockbuster status in first year
2015: 100,000 Genomes Project taps Big Pharma dream team for data crunching skills
2015: Biogen Alzheimer's Drug Scores, Stock Hits High BIIB
2015: Biogen is cutting 830 jobs and pruning its pipeline, betting the future on Alzheimer's R&D
2015: Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed BIIB ABBV
2015: Biogen, AGTC Link Up To Develop Gene Therapy BIIB AGTC
2015: UPDATED: In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study